A PDUFA date is FDA’s goal to act on a drug application. How the clock is set, when it extends by three months, and what happens on decision day.
Last updated: November 13, 2026
A PDUFA date is the goal date by which FDA aims to act on a drug or biologic application under the Prescription Drug User Fee Act. For a new molecular entity it falls 10 months (standard) or 6 months (priority) after the 60 day filing date. It is a goal, not a legal deadline.
Scope: how FDA sets the PDUFA goal date under PDUFA VII, the milestones inside the review, what can move the date, what the possible outcomes are, and what PDUFA VIII may change from October 2027.
What is a PDUFA date?
A PDUFA date, formally the PDUFA goal date or goal action date, is the date by which FDA has committed to review and act on an application. The commitment comes from the user fee agreement FDA negotiates with industry every five years, not from a statute that forces a decision on that day.
The current agreement, PDUFA VII, covers fiscal years 2023 through 2027. FDA’s goal is to act on 90 percent of applications in each category by the goal date. That is why investors and sponsors treat the date as a near certainty, and why a miss is news.
This weekend shows how the date frames a market. Summit Therapeutics said in January that FDA gave its ivonescimab application, for use with chemotherapy in EGFR mutated non squamous non small cell lung cancer after tyrosine kinase inhibitor therapy, “a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.” That is a Saturday. FDA can and often does act before the goal date, so a decision can land on Friday or earlier.
How is the PDUFA goal date calculated?
It depends on the application type and review designation. For new molecular entity NDAs and original BLAs, the clock starts at the end of the 60 day filing review, so total time from submission is roughly 12 months standard or 8 months priority. For other applications, the clock starts at receipt.
| Application type | Standard review goal | Priority review goal | Clock starts |
|---|---|---|---|
| New molecular entity NDA or original BLA | 10 months | 6 months | 60 day filing date (about 12 or 8 months from submission) |
| Non NME original NDA | 10 months | 6 months | Receipt |
| Efficacy supplement (new indication) | 10 months | 6 months | Receipt |
| Class 1 resubmission after a complete response | 2 months | Receipt | |
| Class 2 resubmission after a complete response | 6 months | Receipt | |
Source: FDA, PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027. Each goal applies to 90 percent of submissions in the category.
Priority review is generally assigned at filing when a drug may offer a significant improvement in safety or effectiveness for a serious condition. It changes the clock, not the evidence bar.
What is the difference between a Class 1 and Class 2 resubmission?
A Class 1 resubmission is limited to a short list of items, such as final labeling, safety updates, stability data, postmarketing commitments, assay validation or a minor reanalysis. Everything else is Class 2, including anything that would need an advisory committee. Class 1 gets a 2 month goal; Class 2 gets 6 months.
The classification matters commercially. A complete response letter that only asks for labeling or a minor fix can turn around in a quarter. One that requires a new facility inspection or new clinical analysis resets you to a 6 month wait, and often longer once you count the time to prepare the resubmission.
What happens between filing and the PDUFA date?
For new molecular entities and original biologics, PDUFA VII sets out a structured “Program” with fixed touchpoints. Knowing them lets you read the signals well before decision day.
| Milestone | Timing under PDUFA VII | What it tells you |
|---|---|---|
| Pre submission meeting | Generally at least 2 months before planned submission | Agreement on content and format |
| Filing decision | 60 days after receipt | Accepted, or Refuse to File |
| Day 74 letter | Within 74 calendar days of receipt | Review issues identified, planned mid cycle date, preliminary advisory committee plans |
| Mid cycle communication | Generally within 2 weeks of FDA’s internal mid cycle meeting | Significant issues so far |
| Inspections | Completed within 6 months (priority) or 10 months (standard) of receipt | Manufacturing readiness |
| Advisory committee, if held | No later than 2 months (standard) or 6 weeks (priority) before the goal date | Outside expert vote; not binding |
| Late cycle meeting | Without an advisory committee, no later than 3 months (standard) or 2 months (priority) before the goal date | Major deficiencies and labeling direction |
| Postmarketing requirement discussions | No later than 8 weeks (standard) or 6 weeks (priority) before the goal date | FDA is working toward a label |
The last row is one of the most useful quiet signals. When FDA starts talking postmarketing requirements and labeling, the review is usually heading toward approval. Silence on labeling late in the cycle is worth asking about.
Can FDA extend a PDUFA date?
Yes, once per review cycle. Under PDUFA VII, a major amendment to an original application, efficacy supplement or resubmission “submitted at any time during the review cycle, may extend the goal date by three months.” Amendments to manufacturing supplements extend the date by two months.
The letter also says extensions should, except in rare cases, be limited to situations where reviewing the new information could fix outstanding deficiencies and lead to approval in the current cycle. That is why a three month extension is often read as a mildly positive sign: FDA chose to keep reviewing instead of issuing a complete response letter.
A separate provision lets the goal date move by three months (two for manufacturing supplements) when FDA needs to inspect a facility that was not listed in the application. That trap catches sponsors who add a contract manufacturer late.
What are the possible outcomes on a PDUFA date?
- Approval. FDA issues an approval letter with final labeling. It can arrive days or weeks early. We covered Ultragenyx’s Fayuvi approval two days early and Scholar Rock’s Isembyld 19 days early.
- Complete response letter. FDA declines to approve in this cycle and explains the deficiencies. The sponsor can resubmit as Class 1 or Class 2.
- Extension. If a major amendment came in, the date may have already moved three months.
- Silence. FDA misses the goal. It happens, often around inspections, staffing or leadership churn, and the sponsor usually discloses it.
FDA does not usually announce decisions itself on the day. Most outcomes reach the market through a company press release or an 8-K, which is why after hours and weekend releases cluster around goal dates.
Is a PDUFA date a legal deadline?
No. It is a performance goal FDA agreed to in exchange for user fees, measured across the whole portfolio at 90 percent. Missing one date does not trigger approval or any automatic remedy. The pressure is reputational and contractual: FDA reports its performance against the goals, and those numbers feed the next reauthorization.
That distinction matters more in 2026. Reuters reported on November 12 that FDA shelved its Commissioner’s National Priority Voucher pilot, which promised 1 to 2 month reviews outside the PDUFA framework. HHS says that pilot is ongoing. Either way, the episode shows that PDUFA goals, written into a negotiated agreement, are the review timelines sponsors can actually plan around.
What will PDUFA VIII change?
PDUFA must be reauthorized every five years. PDUFA VII runs through September 2027, and FDA lists PDUFA VIII as covering fiscal years 2028 through 2032. Congress has to pass the reauthorization before the current program lapses.
According to an August 26, 2026 Akin Gump alert, FDA released the proposed PDUFA VIII commitment letter in August, held a public meeting on September 16, 2026, took comments until October 16, 2026, and plans to send the package to Congress by January 15, 2027. Akin Gump highlighted a proposed 50 percent application fee reduction for applications that include data from at least one phase 1 trial anchored in the United States and started after October 1, 2027, a third party assessment of first cycle review, and up to 10 rare disease workshops. We have not verified whether the core 10 and 6 month review goals change; check the final letter.
The fees are already large. FDA’s fiscal 2027 rates, published July 30, 2026, set the application fee with clinical data at $4,600,753 and the annual program fee at $416,857.
How should teams plan around a PDUFA date? Our checklist
This is our framework for regulatory, commercial and investor relations teams.
- Write down the clock math. Submission date, 60 day filing date, review designation and goal date, with the source letter for each.
- Map the Program milestones. Put Day 74, mid cycle, late cycle and any advisory committee on the calendar and note what each communication said.
- List every facility. Confirm every manufacturing and testing site is in the application to avoid an inspection extension.
- Decide in advance on amendments. Know which new data you would submit mid review and accept that it may cost three months.
- Prepare for early action. Have launch, labeling and disclosure materials ready weeks before the goal date, not days.
- Script all four outcomes. Approval, complete response, extension and silence each need a release and an internal plan.
- Classify the fix fast. If a complete response arrives, decide within days whether the resubmission can be Class 1.
What to watch next
- Summit’s ivonescimab goal date on Saturday, November 14, 2026.
- Capricor’s deramiocel, which carries a November 22 goal date, per our August coverage.
- The Senate committee vote on FDA commissioner nominee Heidi Overton, scheduled for November 18 per BioSpace.
- FDA’s transmittal of the PDUFA VIII package to Congress, targeted by January 15, 2027.
FAQ
What does PDUFA stand for?
The Prescription Drug User Fee Act. It lets FDA collect fees from drug sponsors in exchange for meeting agreed review goals, and it is reauthorized every five years.
How long after submission is a PDUFA date?
For a new molecular entity, about 12 months under standard review or 8 months under priority review, because the 10 or 6 month clock starts after the 60 day filing period. For other applications it is 10 or 6 months from receipt.
Can FDA approve a drug before the PDUFA date?
Yes. The goal date is the latest target, not a fixed release day. Early approvals of days or weeks are common.
What happens if FDA misses a PDUFA date?
Nothing automatic. The application stays under review until FDA acts. The sponsor usually discloses the miss, and FDA’s overall performance is reported against the 90 percent goal.
How long is a PDUFA extension?
Three months for a major amendment to an original application, efficacy supplement or resubmission, and two months for a manufacturing supplement. Only one extension is allowed per review cycle.
Is a PDUFA extension good or bad?
It is ambiguous but often mildly positive, because FDA is meant to extend only when the new information could lead to approval in the current cycle.
What is a complete response letter?
FDA’s letter declining to approve an application in its current form and explaining the deficiencies. The sponsor can resubmit, which starts a 2 or 6 month clock depending on the class.
What is a Day 74 letter?
FDA’s filing communication for new molecular entities and original biologics, sent within 74 days of receipt. It flags review issues and gives preliminary plans for an advisory committee.
Does an advisory committee vote decide approval?
No. Advisory committees are not binding. Under PDUFA VII they are generally held at least 2 months (standard) or 6 weeks (priority) before the goal date.
What happens if a PDUFA date falls on a weekend?
The goal is to act by that date, so FDA can act on any earlier day. Sponsors usually disclose the outcome by press release, which can come over the weekend or on the next business day.
When does PDUFA VII expire?
At the end of September 2027. PDUFA VIII would cover fiscal years 2028 through 2032 if Congress passes it.
Sources
- FDA, PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027 (PDUFA VII commitment letter), sections I.A, I.B and appendix (primary).
- FDA, Prescription Drug User Fee Amendments page, content current as of November 3, 2026 (primary: reauthorization cycle, FY2027 fee rates).
- Summit Therapeutics, BLA acceptance release, January 2026, via Business Wire (primary: November 14, 2026 goal date).
- Akin Gump, “PDUFA VIII Pushes Forward,” August 26, 2026 (attributed: proposed letter timing, public meeting, comment period, transmittal target, proposed changes).
- Reuters, November 12, 2026, and BioSpace, November 12, 2026 (attributed: CNPV report, Overton vote date).
Related coverage
- FDA voucher program reportedly shelved: what sponsors face now
- FDA approval pathways and designations explained
- FDA accelerated approval: confirmatory trial rules explained
- PMA not approvable letter: what FDA device rejections mean
- Scholar Rock’s Isembyld won approval 19 days early
- Capricor’s deramiocel gets a November 22 PDUFA date
Track every PDUFA date that matters in our daily briefing: subscribe to BioMed Nexus.
